Banque Cantonale Vaudoise’s Gain Therapeutics GANX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$16K	–	1339
2021 Q4	$16K	Hold	3,000	–	–	﹤0.01%	1204
2021 Q3	$22K	Hold	3,000	–	–	﹤0.01%	1152
2021 Q2	$30K	Buy	+3,000	New	+$33.8K	﹤0.01%	1118

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Banque Cantonale Vaudoise's GANX Position: Q1 2022 in Review

Banque Cantonale Vaudoise sold out of Gain Therapeutics (GANX) in Q1 2022, closing a stake of 3,000 shares — an estimated $16K sold.

Banque Cantonale Vaudoise first reported a position in GANX in Q2 2021 and held it in 3 quarters. The position peaked at $30K in Q2 2021. 16 funds tracked by Wall St. Rank hold GANX as of Q1 2022.

Banque Cantonale Vaudoise reported no remaining Gain Therapeutics position as of Q1 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 3,000 Gain Therapeutics shares in Q1 2022, an estimated $16K.
Banque Cantonale Vaudoise first reported a position in Gain Therapeutics in Q2 2021 and held it in 3 quarters.
Banque Cantonale Vaudoise's Gain Therapeutics position peaked at $30K in Q2 2021.
16 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2022, filed 9 May 2022.